Patients with HER2-positive cancers, which include approximately 20-25% of breast cancer cases and a smaller percentage of gastric cancers, may benefit from trastuzumab. HER2 positivity is determined through tests such as Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH).
